Timing of final oncologist visit and systemic treatment use
near the end of life in pretreated patients with metastatic
triple-negative breast cancer: a multinational cohort study

J 2026

Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study

ZUBROWSKA, Justyna; Malgorzata PIENIAZEK; Anna POLAKIEWICZ-GILOWSKA; Lenka RUSINOVA; Renata SOUMAROVA et al.

Základní údaje

Originální název

Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study

Autoři

Vydání

BREAST, EDINBURGH, CHURCHILL LIVINGSTONE, 2026, 0960-9776

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.900 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Triple negative breast cancer; Palliative systemic therapy; Palliative care integration; End-of-life care; Real-world data

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 4. 2026 10:42, Mgr. Tereza Miškechová

Anotace

V originále

Background: In heavily pretreated patients with metastatic triple-negative breast cancer (mTNBC), further systemic therapy offers limited benefit and increased toxicity. Recognizing the end-of-life (EOL) phase in time helps avoid overtreatment and ensure goal-concordant care. This study analyzed the interval between the last oncologist visit and death in pretreated women with mTNBC, as well as systemic therapy status, palliative care involvement and related factors. Methods: This multinational ambispective cohort study included women with mTNBC who received >= 2 lines of palliative systemic therapy and died between June 20, 2022 and June 20, 2025. Data from 17 centers in Poland, the Czech Republic and Slovakia were extracted from medical records. The primary endpoint was the interval between the final oncologist visit and death. Results: 183 women with median age at death 53.6 years (28.6-86.5) were included. Patients had a median of 4 prior palliative chemotherapy lines (2-12) and the median interval from last oncologist visit to death was 17 days (0-410). At the final visit, 29.5 % continued systemic therapy and 49 % had prior palliative care involvement. Longer intervals were associated with PS 0-1 vs >= 2 (p = 0.005), while palliative care involvement had no significant effect (p = 0.849). Conclusions: The results highlight the need for earlier recognition of clinical decline and timely palliative care in mTNBC. Limiting non-beneficial systemic therapy near EOL supports symptom control, autonomy, and quality of life. Despite European efforts, including the Network of Expertise on Complex and Poor Prognosis Cancers, structured EOL planning remains a major gap.

Citovat

ZUBROWSKA, Justyna; Malgorzata PIENIAZEK; Anna POLAKIEWICZ-GILOWSKA; Lenka RUSINOVA; Renata SOUMAROVA; Hana STUDENTOVA; Aleksandra KONIECZNA; Agnieszka MLODZINSKA; Karolina WINSKO-SZCZESNOWICS; Maja LISIK-HABIB; Anika PEKALA; Daniel KREJCI; Jan SUSTR; Iveta KOLAROVA; Iwona DANIELEWICZ; Magdalena SZYMANIK-RESKO; Tomasz CISZEWSKI; Miloš HOLÁNEK; Bogumila CZARTORYSKA-ARLUKOWICZ; Aleksandra LACKO; Jolanta SMOK-KALWAT; Michal JARZAB; Renata PACHOLCZAK-MADEJ; Iwona LUGOWSKA; Zuzana BIELCIKOVA; Miroslava MALEJCIKOVA a Miroslawa PUSKULLUOGLU. Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study. BREAST. EDINBURGH: CHURCHILL LIVINGSTONE, 2026, roč. 85, February 2026, s. 1-8. ISSN 0960-9776. Dostupné z: https://doi.org/10.1016/j.breast.2026.104699.

@article{2565443,
   author = {Zubrowska, Justyna and Pieniazek, Malgorzata and PolakiewiczandGilowska, Anna and Rusinova, Lenka and Soumarova, Renata and Studentova, Hana and Konieczna, Aleksandra and Mlodzinska, Agnieszka and WinskoandSzczesnowics, Karolina and LisikandHabib, Maja and Pekala, Anika and Krejci, Daniel and Sustr, Jan and Kolarova, Iveta and Danielewicz, Iwona and SzymanikandResko, Magdalena and Ciszewski, Tomasz and Holánek, Miloš and CzartoryskaandArlukowicz, Bogumila and Lacko, Aleksandra and SmokandKalwat, Jolanta and Jarzab, Michal and PacholczakandMadej, Renata and Lugowska, Iwona and Bielcikova, Zuzana and Malejcikova, Miroslava and Puskulluoglu, Miroslawa},
   article_location = {EDINBURGH},
   article_number = {February 2026},
   doi = {https://doi.org/10.1016/j.breast.2026.104699},
   keywords = {Triple negative breast cancer; Palliative systemic therapy; Palliative care integration; End-of-life care; Real-world data},
   language = {eng},
   issn = {0960-9776},
   journal = {BREAST},
   title = {Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study},
   url = {https://www.sciencedirect.com/science/article/pii/S0960977626000093?via%3Dihub},
   volume = {85},
   year = {2026}
}

TY  - JOUR
ID  - 2565443
AU  - Zubrowska, Justyna - Pieniazek, Malgorzata - Polakiewicz-Gilowska, Anna - Rusinova, Lenka - Soumarova, Renata - Studentova, Hana - Konieczna, Aleksandra - Mlodzinska, Agnieszka - Winsko-Szczesnowics, Karolina - Lisik-Habib, Maja - Pekala, Anika - Krejci, Daniel - Sustr, Jan - Kolarova, Iveta - Danielewicz, Iwona - Szymanik-Resko, Magdalena - Ciszewski, Tomasz - Holánek, Miloš - Czartoryska-Arlukowicz, Bogumila - Lacko, Aleksandra - Smok-Kalwat, Jolanta - Jarzab, Michal - Pacholczak-Madej, Renata - Lugowska, Iwona - Bielcikova, Zuzana - Malejcikova, Miroslava - Puskulluoglu, Miroslawa
PY  - 2026
TI  - Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study
JF  - BREAST
VL  - 85
IS  - February 2026
SP  - 1-8
EP  - 1-8
PB  - CHURCHILL LIVINGSTONE
SN  - 09609776
KW  - Triple negative breast cancer
KW  - Palliative systemic therapy
KW  - Palliative care integration
KW  - End-of-life care
KW  - Real-world data
UR  - https://www.sciencedirect.com/science/article/pii/S0960977626000093?via%3Dihub
N2  - Background: In heavily pretreated patients with metastatic triple-negative breast cancer (mTNBC), further systemic therapy offers limited benefit and increased toxicity. Recognizing the end-of-life (EOL) phase in time helps avoid overtreatment and ensure goal-concordant care. This study analyzed the interval between the last oncologist visit and death in pretreated women with mTNBC, as well as systemic therapy status, palliative care involvement and related factors. Methods: This multinational ambispective cohort study included women with mTNBC who received >= 2 lines of palliative systemic therapy and died between June 20, 2022 and June 20, 2025. Data from 17 centers in Poland, the Czech Republic and Slovakia were extracted from medical records. The primary endpoint was the interval between the final oncologist visit and death. Results: 183 women with median age at death 53.6 years (28.6-86.5) were included. Patients had a median of 4 prior palliative chemotherapy lines (2-12) and the median interval from last oncologist visit to death was 17 days (0-410). At the final visit, 29.5 % continued systemic therapy and 49 % had prior palliative care involvement. Longer intervals were associated with PS 0-1 vs >= 2 (p = 0.005), while palliative care involvement had no significant effect (p = 0.849). Conclusions: The results highlight the need for earlier recognition of clinical decline and timely palliative care in mTNBC. Limiting non-beneficial systemic therapy near EOL supports symptom control, autonomy, and quality of life. Despite European efforts, including the Network of Expertise on Complex and Poor Prognosis Cancers, structured EOL planning remains a major gap.
ER  -

ZUBROWSKA, Justyna; Malgorzata PIENIAZEK; Anna POLAKIEWICZ-GILOWSKA; Lenka RUSINOVA; Renata SOUMAROVA; Hana STUDENTOVA; Aleksandra KONIECZNA; Agnieszka MLODZINSKA; Karolina WINSKO-SZCZESNOWICS; Maja LISIK-HABIB; Anika PEKALA; Daniel KREJCI; Jan SUSTR; Iveta KOLAROVA; Iwona DANIELEWICZ; Magdalena SZYMANIK-RESKO; Tomasz CISZEWSKI; Miloš HOLÁNEK; Bogumila CZARTORYSKA-ARLUKOWICZ; Aleksandra LACKO; Jolanta SMOK-KALWAT; Michal JARZAB; Renata PACHOLCZAK-MADEJ; Iwona LUGOWSKA; Zuzana BIELCIKOVA; Miroslava MALEJCIKOVA a Miroslawa PUSKULLUOGLU. Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study. \textit{BREAST}. EDINBURGH: CHURCHILL LIVINGSTONE, 2026, roč.~85, February 2026, s.~1-8. ISSN~0960-9776. Dostupné z: https://doi.org/10.1016/j.breast.2026.104699.

Přehled o publikaci